Alzheimer's Disease And Dementia
Currently, there are no approved treatments for behavioral symptoms in Alzheimer disease.
Investigators reviewed data from patients aged 45 to 64 years who were enrolled in the Atherosclerosis Risk in Communities Study and who attended additional visits for cognitive function evaluation and repeat cardiovascular risk factor assessment.
An international team of investigators assessed the ability of flutemetamol F 18-labeled PET and other biomarkers to predict risk of clinical progression from amnestic mild cognitive impairment to probable Alzheimer disease.
For an unselected memory clinic cohort, amyloid PET results are associated with changes in etiology, diagnostic confidence, and patient treatment.
While hundreds of published reports have made an argument for an association between Alzheimer disease and bacteria and viruses, the suggestion of a viral contribution to Alzheimer disease has not always been well received by the greater research community.
Phase 3 clinical trials for lanabecestat (Eli Lilly and AstraZeneca), an investigational Alzheimer disease treatment, are being discontinued for futility.
The risk of dementia is increased in 50-year-olds with blood pressure ≥130 mm Hg, which is below the current threshold for hypertension.
The lifetime risks of Alzheimer disease dementia vary considerably by age, gender, and the preclinical or clinical disease state.
There was an observable pattern with combined polyphenol intake and risk for dementia in the study cohort.
Janssen announced that the Company will no longer continue studying atabecestat, an investigational treatment for asymptomatic patients at risk for developing Alzheimer disease.
These results suggest that antipsychotic exposure has no impact on relative mortality.
Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.
Methylphenidate demonstrated an improvement in apathy vs placebo when measured by the apathy evaluation scale, in addition, methylphenidate showed possible improvement in cognition.
Use of anticholinergic drugs may be tied to a future diagnosis of dementia.
Additional examination of these relationships is warranted to help clarify the complex biologic and psychosocial interactions among Alzheimer disease, malignant melanoma, and nonmelanoma skin cancer.
Results showed that after 18-months, there was no significant statistical difference in cognitive or functional outcomes between those patients taking azeliragon and the placebo group.
About half of adults surveyed expect a man with mild Alzheimer dementia to be discriminated against.
Findings show lower post-surgical mortality among patients with Alzheimer's disease.
Molecular markers can identify changes associated with the disease before clinical onset for young adults with autosomal dominant AD.
Merck announced the discontinuation of the Phase 3 APECS study for the treatment of AD.
Positive beliefs on age may protect against dementia.
The use of DBS in patients with Alzheimer disease is well tolerated and associated with less decline on the CDR-SB.
A study was conducted to assess potential beneficial effects of a lifestyle intervention program on cognition in carriers of the APOE ε4 allele.
Solanezumab does not alter cognitive decline in patients with mild Alzheimer disease.
Brain amyloidosis is associated with certain Alzheimer disease risk variants.
Because of dementia's prolonged disease course, advance care decisions and planning are often overlooked until it is too late.
For patients with mild-to-moderate Alzheimer disease, the use of idalopirdine does not improve cognition.
There is an increased risk of dementia for patients with rheumatic diseases.
A hanful of studies reviewed the different types of interventions to prevent late-life dementia.
Throughout the life course, higher body mass index and obesity are linked to cognitive decline, brain atrophy, reduced white matter and integrity of the blood-brain barrier, and elevated risk for late-onset Alzheimer disease.
Neurology Advisor Articles
- Addressing Rare Headache Disorders: Acute Confusional Migraine
- Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis
- No Significant Clinical Differences Between Cluster Headaches With and Without Aura
- Co-Prescription of Opioids and Antidepressants Prevalent in Migraine
- Deep Brain Stimulation May Slow Rest Tremor Progression in Parkinson Disease
- Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds
- Patients' Preferences for Physician Attire Linked to Perception of Care
- Weighing the Risks of Deep Brain Stimulation
- Grey Matter Atrophy Sequence in Multiple Sclerosis Phenotypes
- Higher Vitamin D Levels Associated With Fewer Lesions in Multiple Sclerosis
- Screening Tool Differentiates Progressive Supranuclear Palsy and Parkinson Disease
- Risk Factors for Impulse Control Behaviors in Parkinson Disease
- Cardiac Pathology in SUDEP Compared With Sudden Arrhythmic or Traumatic Deaths
- 11.2% of U.S. Adults Aged ≥45 Report Subjective Mental Decline
- AMA Aims to Boost Affordability of ACA Marketplace Plans